“This additional capacity is a critical step in helping us capitalize on our solutions for agriculture to achieve a food secure future,” says Mark Singleton, head of plant health at RTP. “The investment will help us stay at the forefront of innovation and pursue unique advancements as we are currently seeing in our fungal program.”
“We plan to have 60 employees on site by the end of 2022, with our new spaces housing various entomology, fungal and herbicide projects and the functions that support them.”
“GreenLight embodies the type of business we envision for our Center in Alexandria® for the AgTech campus, a fully integrated and equipment-rich R&D and greenhouse campus, ”said Blake stevens, vice president of science and technology, Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments.
“With the transformative potential of GreenLight’s RNA platform, we have both invested in and provided the business with critical real estate, and we are delighted to support their rapid growth and efforts to improve. human health and nutrition significantly in the second phase of our one-of-a-kind agtech campus.
Occupancy of the new greenhouse, where GreenLight will plant a variety of crops, will begin in the first quarter and increase growth capacity tenfold. The operations will support research and product development as the company strives to bring innovative new tools to farmers to control pests and diseases, including botrytis and powdery mildew.
In 2022, GreenLight is awaiting regulatory approval for its RNA-based product to monitor the Colorado Colorado potato beetle and submit its bee health solution to the Environmental Protection Agency.
The company has seven developing agricultural products with an addressable market of $ 6 billion which it plans to launch by 2026. In October, GreenLight announced that effective control of fungal pathogens using double-stranded RNA had been achieved for the first time.
Founded in 2008, GreenLight aims to solve some of the world’s biggest problems by harnessing the full potential of RNA for human health and agriculture. In human health, this includes mRNA vaccines and therapeutic products. In agriculture, this includes RNA to protect bees and a range of crops. The company’s revolutionary cell-free RNA manufacturing platform, which is protected by numerous patents, enables cost-effective RNA production. GreenLight’s human health product candidates are in the preclinical stage and its agricultural market product candidates are in the early stages of development or regulatory review. For more information visit https://www.greenlightbiosciences.com/
In August 2021, GreenLight Biosciences announced its intention to be publicly traded through a business combination with Environmental Impact Acquisition Corp. (Nasdaq: ENVI).
This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding the proposed transaction between GreenLight Biosciences, Inc. (“GreenLight”) and Environmental Impact Acquisition . Corp. (“ENVI”). These forward-looking statements are generally identified by the words “believe”, “plan”, “expect”, “anticipate”, “estimate”, “intend”, “the strategy”, “the future”, ” opportunity “,” plan, “” may “,” should “,” will “,” would “,” will “,” continue “,” will probably result “and similar expressions. There are many factors that could cause actual future events to differ materially from the forward-looking statements contained in this press release, including, but not limited to, the risk that the transaction will not be completed on time or not at all. , which could adversely affect the price of the securities of ENVI and the effect of the announcement or expectation of the transaction on the business relationships, results of operations and the affairs of GreenLight in general. Forward-looking statements speak only as of the date on which they are made. Readers are cautioned not to place undue reliance on forward-looking statements, and ENVI and GreenLight assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE GreenLight Biosciences, Inc.